
    
      This study will be conducted at 1 study center in China. Approximately 42 healthy Chinese
      male and female subjects, aged 18 to 55 inclusive, will be randomized to receive a single SC
      administration of SHR-1703: Treatment 1, Treatment 2, Treatment 3, Treatment 4 and Treatment
      5. Each subject will participate in only 1 treatment group. The total length of the study for
      each subject is up to 190 days (28 days of screening and 155+/- 7 days of further study
      visits).
    
  